Asia Pacific Artificial Heart Market is anticipated to rise at an impressive rate through 2028 due to the increasing number of heart strokes, coronary heart disease (CHD) and other heart related disorders. Moreover, developing unhealthy lifestyles of people which includes their food habits, alcohol consumption, cigarette smoking, and others is further contributing to growth of the market.
Growing Prevalence of Cardiac Disorders
Journal of the American College of Cardiology (JACC) report, CVD was the leading cause of death in Asia in 2019, causing 10.8 million deaths, which were approximately 35% of the total deaths in Asia. 39% of these CVD deaths were premature (defined as the death of a person age <70 years).
Poor Lifestyle of People
highest age-standardized rate of diet-related CVD deaths (299 per 100,000 population) was reported.
Increasing Geriatric Population
According to the report published in 2020, it has been analyzed that around 8.1 million of senior citizens are suffering from heart diseases in India which is expected to increase till 11.1 million of geriatric population by 2030.
Technological Advancements
In modern times, advancements associated with artificial intelligence and data sciences have emerged as a boon and paving way for the growth of Artificial Heart Market in the region. Health professionals from various countries are investing in research and development for improved outcome of artificial heart implantations. Moreover, growing awareness among the people of Asia-Pacific region has made the artificial heart market to be the most recommended for treatment related to biventricular heart failure. Various other cardiac surgeries where artificial intelligence and machine learning is assisting with the medical help in their procedure is further accounting for the impressive growth of Asia Pacific Artificial Heart Market in upcoming years.
Key Developments
- Recently in 2021, Modern Heart and VascularInstitute have reported that Chinese researchers are making use of aerospacetechnology to design an artificial heart. On January 13, 2021, a medical teamimplanted the aerospace artificial heart into a person suffering from heartfailure. The developed artificial heart was named HeartCon, which was successful in pumping and deliveringblood throughout the body to alleviate heart failure symptoms.
- As per the report publishedby Digital Journal on February 28, 2023, Eko, a digital health company workingagainst heart and lung diseases by use of Artificial Intelligence (AI) announcingthe launch of SENSORA which is a platform for detecting cardiac diseases byidentifying structural murmurs and signs of valvular heart disease. Moreover,they launched Care Pathway Analytics software that provides downstreamvisibility and metrics of the patient journey throughout the healthcare system.
- As per the report publishedby Victor Chang Cardiac Research Institute, Australia under AustralianGovernment TTRA grant, Professor Hayward's team based at the institute incollaboration with St Vincent's Hospital in Sydney, conducted studies toprepare BiVACOR device for transplantation which was planned to be clinicallytried in late 2022/early 2023. The study focused on placing the device in chestof cardiac diseased patient to learn about its fit and placement.
Download Free Sample Report
Market Segmentation
Asia Pacific Artificial Heart Market is segmented based on type, power source, end-user, country, and company. In terms of type, the Artificial Heart Market is categorized into ventricular assist device, total artificial heart, and others. Based on power source, the market is divided into internal battery and external battery. Based on end-user, the market is segmented into
Market Players
BiVACOR, Pty. Ltd., Nikkiso Co., Ltd., SynCardia Systems, LLC, Abbott Laboratories, Inc., Rocor Medical Technology Co, Ltd., CryoLife, Inc., Medtronic Plc., Sun Medical Technology Research Corp, Abiomed, Inc., Terumo Corporation
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2018 – 2028F |
Quantitative Units | Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | Type Power Source End User Industry |
Regional scope | Asia Pacific |
Country scope | China; India; Japan; South Korea; Australia; Malaysia; Indonesia; Singapore; Taiwan; Vietnam; |
Key companies profiled | BiVACOR, Pty. Ltd., Nikkiso Co., Ltd., SynCardia Systems, LLC, Abbott Laboratories, Inc., Rocor Medical Technology Co, Ltd., CryoLife, Inc., Medtronic Plc., Sun Medical Technology Research Corp, Abiomed, Inc., Terumo Corporation. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |